Sweden's Nanologica Q4 sales fall

Nanologica AB (publ)

26/02/2026 07:19

Overview

Swedish life science tools firm's Q4 net sales declined yr/yr

Company's full-year sales increased 45% yr/yr

Company acquired Ardena Södertälje to strengthen production capabilities

Outlook

Nanologica expects 2026 earnings boost from Ardena Södertälje acquisition

Company anticipates 2025 turnover of SEK 100 mln, up from SEK 21 mln

Nanologica aims to lower production costs and shorten lead times

Result Drivers

ORDER DELIVERIES - Q4 sales included delivery of NLAB Saga® for insulin production evaluation, indicating potential for future sales

PRODUCTION STABILIZATION - Since September, production improvements have increased throughput, paving way for future sales growth

ACQUISITION IMPACT - Acquisition of Ardena Södertälje expected to enhance production capacity and contribute positively to earnings in 2026

Company press release: ID:nMFN7n7JnY

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
SEK 5.21 mln
Q4 Adjusted EPS
-SEK 0.19


Analyst Coverage

Wall Street's median 12-month price target for Nanologica AB (publ) is SEK3.00, about 710.8% above its February 25 closing price of SEK0.37

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)